WHO ICTRP trial
A study of HT-6184 in subjects with Myelodysplastic Syndrome (MDS) and…
CTRI/2023/11/059758 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/11/059758 |
|---|---|
| Public title | A study of HT-6184 in subjects with Myelodysplastic Syndrome (MDS) and Symptomatic Anemia. |
| Scientific title | A Phase 2a study of HT-6184 in subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia. - NIL |
| Primary sponsor | Halia Therapeutics |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India;United States of America |
| Conditions | Health Condition 1: D469- Myelodysplastic syndrome, unspecified |
| Interventions | Intervention1: HT-6184 2 mg capsule for 8 months (32 weeks) of Halia Therapeutics.: Dose: 2 mg, Frequency: administration for 5 days followed by a 2 days drug holiday, Route of Administration: Oral, Duration of Therapy: The duration from… |
| Registration date | Nov 13, 2023 |
| Target size | 40 |
| Secondary IDs | HT-618-MDS-001, Version No. 5.0 dated 26/Feb/2025;HT-6184-MDS-001 Version No. 3.0 dated 15/May/2023;HT-6184-MDS-001, Version No. 4.0 dated 01/Jul/2024 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: